Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 3/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23956123 | 0.87 | HTR2A (0.56) | MEN1NPC1RAB9AKMT2AHTR7 | |
| SCHEMBL25631028 | 0.83 | SCN9A (0.55) | MEN1NPC1RAB9AKMT2AHTR7 | |
| Fumaric Acid SCHEMBL23927870 | 0.80 | SRD5A2 (0.51) | MEN1NPC1RAB9AKMT2ASRD5A2 | |
| SCHEMBL17602263 | 0.80 | MEN1 (0.56) | MEN1NPC1RAB9AKMT2AHTR7 | |
| SCHEMBL4191518 | 0.78 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHTR7 | |
| SCHEMBL27639042 | 0.78 | ALOX5 (0.55) | MEN1NPC1RAB9AKMT2AHTR7 | |
| SCHEMBL23927885 | 0.78 | HTR2A (0.66) | MEN1NPC1RAB9AKMT2AHTR7 | |
| SCHEMBL25630553 | 0.78 | MEN1 (0.54) | MEN1NPC1RAB9AKMT2AHTR7 | |
| SCHEMBL3927600 | 0.77 | MEN1 (0.53) | MEN1NPC1RAB9AKMT2AHTR7 | |
| SCHEMBL6097633 | 0.77 | MEN1 (0.53) | MEN1NPC1RAB9AKMT2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | MEN1 995/4885NPC1 721/4885RAB9A 2645/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | MEN1 995/4885NPC1 721/4885RAB9A 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.